Business Description
Harpoon Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US41358P2056
Description
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.18 | |||||
| Equity-to-Asset | 0.1 | |||||
| Debt-to-Equity | 3.19 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.53 | |||||
| Beneish M-Score | 1.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 53.6 | |||||
| 3-Year EBITDA Growth Rate | 8.9 | |||||
| 3-Year EPS without NRI Growth Rate | 7.3 | |||||
| 3-Year FCF Growth Rate | -109.2 | |||||
| 3-Year Book Growth Rate | -65.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 2.19 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 89.84 | |||||
| 9-Day RSI | 84.87 | |||||
| 14-Day RSI | 82.42 | |||||
| 6-1 Month Momentum % | 202.97 | |||||
| 12-1 Month Momentum % | 240.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.8 | |||||
| Shareholder Yield % | -1.58 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -100.14 | |||||
| Net Margin % | -81.67 | |||||
| FCF Margin % | -185.8 | |||||
| ROE % | -498.9 | |||||
| ROA % | -43.72 | |||||
| ROIC % | -102.56 | |||||
| 3-Year ROIIC % | -72.53 | |||||
| ROC (Joel Greenblatt) % | -186.95 | |||||
| ROCE % | -88.39 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.3 | |||||
| PB Ratio | 20.82 | |||||
| Price-to-Tangible-Book | 20.73 | |||||
| EV-to-EBIT | -17.38 | |||||
| EV-to-EBITDA | -18.71 | |||||
| EV-to-Revenue | 12.73 | |||||
| EV-to-Forward-Revenue | 23.18 | |||||
| EV-to-FCF | -6.85 | |||||
| Earnings Yield (Greenblatt) % | -5.75 | |||||
| FCF Yield % | -14.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HARP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Harpoon Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 37.341 | ||
| EPS (TTM) ($) | -8.76 | ||
| Beta | 0 | ||
| Volatility % | 161.27 | ||
| 14-Day RSI | 82.42 | ||
| 14-Day ATR ($) | 0.184916 | ||
| 20-Day SMA ($) | 22.7915 | ||
| 12-1 Month Momentum % | 240.15 | ||
| 52-Week Range ($) | 3.11 - 23.21 | ||
| Shares Outstanding (Mil) | 21.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Harpoon Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Harpoon Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Harpoon Therapeutics Inc Frequently Asked Questions
What is Harpoon Therapeutics Inc(HARP)'s stock price today?
The current price of HARP is $23.01. The 52 week high of HARP is $23.21 and 52 week low is $3.11.
When is next earnings date of Harpoon Therapeutics Inc(HARP)?
The next earnings date of Harpoon Therapeutics Inc(HARP) is 2025-03-01 Est..
Does Harpoon Therapeutics Inc(HARP) pay dividends? If so, how much?
Harpoon Therapeutics Inc(HARP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers